Doliver Advisors, LP Biocryst Pharmaceuticals Inc Transaction History
Doliver Advisors, LP
- $365 Million
- Q3 2025
A detailed history of Doliver Advisors, LP transactions in Biocryst Pharmaceuticals Inc stock. As of the latest transaction made, Doliver Advisors, LP holds 274,328 shares of BCRX stock, worth $1.87 Million. This represents 0.57% of its overall portfolio holdings.
Number of Shares
274,328
Previous 274,328
-0.0%
Holding current value
$1.87 Million
Previous $2.46 Million
15.26%
% of portfolio
0.57%
Previous 0.71%
Shares
4 transactions
Others Institutions Holding BCRX
# of Institutions
315Shares Held
201MCall Options Held
930KPut Options Held
553K-
Vanguard Group Inc Valley Forge, PA20.5MShares$140 Million0.0% of portfolio
-
Black Rock Inc. New York, NY20MShares$136 Million0.0% of portfolio
-
State Street Corp Boston, MA8.51MShares$57.9 Million0.0% of portfolio
-
Kynam Capital Management, LP Princeton, NJ8.46MShares$57.6 Million9.06% of portfolio
-
Alkeon Capital Management LLC New York, NY5.71MShares$38.9 Million0.09% of portfolio
About BIOCRYST PHARMACEUTICALS INC
- Ticker BCRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 185,944,992
- Market Cap $1.27B
- Description
- BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat...